Radnostix Q3 revenue falls on cobalt contract delays
INIS•
INIS•Radnostix said Q3 revenue fell 22% year over year to $2.57 million, citing delays in large Cobalt Products contracts. Theranostics Products sales rose 15%, and the company agreed to sell Fluorine Products and DUF6 assets to Nano Nuclear Energy for $13.5 million, subject to approval.
Radnostix reported Q3 revenue of $2.57 million, down 22% year over year, primarily because large Cobalt Products contracts were delayed while awaiting NRC amendments. Lower Calibration & Reference Products sales also reflected a global cobalt-57 supply interruption.
Theranostics Products sales rose 15% year over year, reflecting customer growth after earlier recall disruptions. Q3 gross profit was $1.51 million.
The company agreed to sell its Fluorine Products and DUF6 assets to Nano Nuclear Energy for $13.5 million, subject to NRC approval and other conditions. Radnostix expects to execute the delayed Cobalt contracts in Q1 2027, pending NRC amendments, and plans to advance commercialization of EasyFill, RadVent and Lara Detection in 2027.